Top

Published in:

Open Access 01-06-2014 | Review

Truncated and modified amyloid-beta species

Authors: Markus P Kummer, Michael T Heneka

Published in: Alzheimer's Research & Therapy | Issue 3/2014

Abstract

Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble aggregates in senile plaques, the histopathological hallmark of the disease. These peptides are also found in soluble, mostly monomeric and dimeric, forms in the interstitial and cerebrospinal fluid. Due to the combination of several enzymatic activities during APP processing, Aβ peptides exist in multiple isoforms possessing different N-termini and C-termini. These peptides include, to a certain extent, part of the juxtamembrane and transmembrane domain of APP. Besides differences in size, post-translational modifications of Aβ – including oxidation, phosphorylation, nitration, racemization, isomerization, pyroglutamylation, and glycosylation – generate a plethora of peptides with different physiological and pathological properties that may modulate disease progression.

Available only for authorised users

Querfurth HW, LaFerla FM: Alzheimer’s disease. N Engl J Med. 2010, 362: 329-344. 10.1056/NEJMra0909142.CrossRefPubMed

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science. 2010, 330: 1774-1774. 10.1126/science.1197623.PubMedCentralCrossRefPubMed

Heneka MT, O’Banion MK, Terwel D, Kummer MP: Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm Vienna Austria 1996. 2010, 117: 919-947.

Thinakaran G, Koo EH: Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008, 283: 29615-29619. 10.1074/jbc.R800019200.PubMedCentralCrossRefPubMed

Kuhn P-H, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF: ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29: 3020-3032. 10.1038/emboj.2010.167.PubMedCentralCrossRefPubMed

Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M: Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999, 286: 735-741. 10.1126/science.286.5440.735.CrossRefPubMed

Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C: Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature. 1992, 359: 325-327. 10.1038/359325a0.CrossRefPubMed

Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C: Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003, 5: 486-488. 10.1038/ncb960.CrossRefPubMed

Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y: γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci Off J Soc Neurosci. 2009, 29: 13042-13052. 10.1523/JNEUROSCI.2362-09.2009.CrossRef

10.

Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y: Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci Off J Soc Neurosci. 2005, 25: 436-445. 10.1523/JNEUROSCI.1575-04.2005.CrossRef

11.

Bibl M, Gallus M, Welge V, Lehmann S, Sparbier K, Esselmann H, Wiltfang J: Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides. Proteomics Clin Appl. 2012, 6: 163-169. 10.1002/prca.201100082.CrossRefPubMed

12.

Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007, 8: 101-112. 10.1038/nrm2101.CrossRefPubMed

13.

Beher D, Wrigley JDJ, Owens AP, Shearman MS: Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. J Neurochem. 2002, 82: 563-575. 10.1046/j.1471-4159.2002.00985.x.CrossRefPubMed

14.

Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K: A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011, 32: 1090-1098. 10.1016/j.neurobiolaging.2009.06.002.CrossRefPubMed

15.

Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ: β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem. 1993, 268: 3021-3024.PubMed

16.

Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K: Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis. 2010, 21: 1005-1012.PubMed

17.

Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K: A novel Aβ isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther. 2010, 2: 7-10.1186/alzrt30.PubMedCentralCrossRefPubMed

18.

Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU: Alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation. J Neurochem. 2009, 111: 1369-1382. 10.1111/j.1471-4159.2009.06420.x.CrossRefPubMed

19.

Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, Frébourg T, Checler F: Unusual phenotypic alteration of beta amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease. Proc Natl Acad Sci USA. 1999, 96: 4119-4124. 10.1073/pnas.96.7.4119.PubMedCentralCrossRefPubMed

20.

Schieb H, Kratzin H, Jahn O, Möbius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW: Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J Biol Chem. 2011, 286: 33747-33758. 10.1074/jbc.M111.246561.PubMedCentralCrossRefPubMed

21.

Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J-P, Vanmechelen E, Sergheraert C, Delacourte A: Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem. 2003, 85: 1581-1591. 10.1046/j.1471-4159.2003.01818.x.CrossRefPubMed

22.

Kalback W, Watson MD, Kokjohn TA, Kuo Y-M, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE: APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry (Mosc). 2002, 41: 922-928. 10.1021/bi015685+.CrossRef

23.

Pike CJ, Overman MJ, Cotman CW: Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J Biol Chem. 1995, 270: 23895-23898. 10.1074/jbc.270.41.23895.CrossRefPubMed

24.

Wang DS, Dickson DW, Malter JS: β-Amyloid degradation and Alzheimer’s disease. J Biomed Biotechnol. 2006, 2006: 58406-PubMedCentralCrossRefPubMed

25.

Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, De Strooper B, Saftig P: Elevation of beta-amyloid peptide 2–42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem. 2001, 276: 42645-42657. 10.1074/jbc.M102790200.CrossRefPubMed

26.

Arai T, Akiyama H, Ikeda K, Kondo H, Mori H: Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer’s disease. Brain Res. 1999, 823: 202-206. 10.1016/S0006-8993(98)01366-3.CrossRefPubMed

27.

Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Rüther E, Wiltfang J: Cerebrospinal fluid amyloid-β 2–42 is decreased in Alzheimer’s, but not in frontotemporal dementia. J Neural Transm Vienna Austria 1996. 2012, 119: 805-813.

28.

Bien J, Jefferson T, Causević M, Jumpertz T, Munter L, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik CU: The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J Biol Chem. 2012, 287: 33304-33313. 10.1074/jbc.M112.395608.PubMedCentralCrossRefPubMed

29.

Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA: Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem. 2012, 287: 8154-8162. 10.1074/jbc.M111.308601.PubMedCentralCrossRefPubMed

30.

Casas C, Sergeant N, Itier J-M, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L: Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004, 165: 1289-1300. 10.1016/S0002-9440(10)63388-3.PubMedCentralCrossRefPubMed

31.

Güntert A, Döbeli H, Bohrmann B: High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006, 143: 461-475. 10.1016/j.neuroscience.2006.08.027.CrossRefPubMed

32.

Drew SC, Masters CL, Barnham KJ: Alanine-2 carbonyl is an oxygen ligand in Cu²⁺ coordination of Alzheimer’s disease amyloid-beta peptide – relevance to N-terminally truncated forms. J Am Chem Soc. 2009, 131: 8760-8761. 10.1021/ja903669a.CrossRefPubMed

33.

Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985, 82: 4245-4249. 10.1073/pnas.82.12.4245.PubMedCentralCrossRefPubMed

34.

Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN: Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol. 2006, 32: 103-118. 10.1111/j.1365-2990.2006.00696.x.CrossRefPubMed

35.

Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA: N-truncated amyloid β (Aβ) 4–42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol (Berl). 2013, 126: 189-205. 10.1007/s00401-013-1129-2.CrossRef

36.

Takeda K, Araki W, Akiyama H, Tabira T: Amino-truncated amyloid beta-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer’s disease brain. FASEB J Off Publ Fed Am Soc Exp Biol. 2004, 18: 1755-1757.

37.

Murayama KS, Kametani F, Tabira T, Araki W: A novel monoclonal antibody specific for the amino-truncated beta-amyloid Aβ5–40/42 produced from caspase-cleaved amyloid precursor protein. J Neurosci Methods. 2007, 161: 244-249. 10.1016/j.jneumeth.2006.11.010.CrossRefPubMed

38.

Portelius E, Olsson M, Brinkmalm G, Rüetschi U, Mattsson N, Andreasson U, Gobom J, Brinkmalm A, Hölttä M, Blennow K, Zetterberg H: Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer’s disease. J Alzheimers Dis. 2013, 33: 85-93.PubMed

39.

Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E: BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PloS One. 2012, 7: e31084-10.1371/journal.pone.0031084.PubMedCentralCrossRefPubMed

40.

Hu J, Igarashi A, Kamata M, Nakagawa H: Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001, 276: 47863-47868.PubMed

41.

Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P: Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA. 1994, 91: 8378-8382. 10.1073/pnas.91.18.8378.PubMedCentralCrossRefPubMed

42.

Hensley K, Aksenova M, Carney JM, Harris M, Butterfield DA: Amyloid beta-peptide spin trapping. I: peptide enzyme toxicity is related to free radical spin trap reactivity. Neuroreport. 1995, 6: 489-492. 10.1097/00001756-199502000-00021.CrossRefPubMed

43.

Palmblad M, Westlind-Danielsson A, Bergquist J: Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1–40 oligomers. J Biol Chem. 2002, 277: 19506-19510. 10.1074/jbc.M112218200.CrossRefPubMed

44.

Hou L, Kang I, Marchant RE, Zagorski MG: Methionine 35 oxidation reduces fibril assembly of the amyloid Aβ-(1–42) peptide of Alzheimer’s disease. J Biol Chem. 2002, 277: 40173-40176. 10.1074/jbc.C200338200.CrossRefPubMed

45.

Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam Y-H, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R: Neurotoxic, redox-competent Alzheimer’s beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003, 278: 42959-42965. 10.1074/jbc.M305494200.CrossRefPubMed

46.

Milton NG: Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. Neuroreport. 2001, 12: 3839-3844. 10.1097/00001756-200112040-00047.CrossRefPubMed

47.

Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wüllner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J: Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease. EMBO J. 2011, 30: 2255-2265. 10.1038/emboj.2011.138.PubMedCentralCrossRefPubMed

48.

Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J: Early intraneuronal accumulation and increased aggregation of phosphorylated Aβ in a mouse model of Alzheimer’s disease. Acta Neuropathol (Berl). 2013, 125: 699-709. 10.1007/s00401-013-1107-8.CrossRef

49.

Kumar S, Singh S, Hinze D, Josten M, Sahl H-G, Siepmann M, Walter J: Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J Biol Chem. 2012, 287: 8641-8651. 10.1074/jbc.M111.279133.PubMedCentralCrossRefPubMed

50.

Radi R, Cassina A, Hodara R, Quijano C, Castro L: Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med. 2002, 33: 1451-1464. 10.1016/S0891-5849(02)01111-5.CrossRefPubMed

51.

Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R: Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer’s disease. Brain Res. 2007, 1148: 243-248.PubMedCentralCrossRefPubMed

52.

Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA: Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem. 2003, 85: 1394-1401. 10.1046/j.1471-4159.2003.01786.x.CrossRefPubMed

53.

Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein DL, Klockgether T: Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol. 2001, 60: 906-916.PubMed

54.

Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB: Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J Exp Med. 1996, 184: 1425-1433. 10.1084/jem.184.4.1425.CrossRefPubMed

55.

Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape H-C, König S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT: Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron. 2011, 71: 833-844. 10.1016/j.neuron.2011.07.001.CrossRefPubMed

56.

Al-Hilaly YK, Williams TL, Stewart-Parker M, Ford L, Skaria E, Cole M, Bucher WG, Morris KL, Sada AA, Thorpe JR, Serpell LC: A central role for dityrosine crosslinking of amyloid-β in Alzheimer’s disease. Acta Neuropathol Commun. 2013, 1: 83-10.1186/2051-5960-1-83.PubMedCentralCrossRefPubMed

57.

Thiabaud G, Pizzocaro S, Garcia-Serres R, Latour J-M, Monzani E, Casella L: Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. Angew Chem Int Ed Engl. 2013, 52: 8041-8044. 10.1002/anie.201302989.CrossRefPubMed

58.

Halim A, Brinkmalm G, Rüetschi U, Westman-Brinkmalm A, Portelius E, Zetterberg H, Blennow K, Larson G, Nilsson J: Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci USA. 2011, 108: 11848-11853. 10.1073/pnas.1102664108.PubMedCentralCrossRefPubMed

59.

Mori H, Takio K, Ogawara M, Selkoe DJ: Mass spectrometry of purified amyloid beta protein in Alzheimer’s disease. J Biol Chem. 1992, 267: 17082-17086.PubMed

60.

Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct beta-amyloid peptide species, AβN3(pE), in senile plaques. Neuron. 1995, 14: 457-466. 10.1016/0896-6273(95)90301-1.CrossRefPubMed

61.

Sevalle J, Amoyel A, Robert P, Fournié-Zaluski M-C, Roques B, Checler F: Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem. 2009, 109: 248-256. 10.1111/j.1471-4159.2009.05950.x.CrossRefPubMed

62.

Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, Lee VM-Y: Characterization of Aβ11–40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease. Acta Neuropathol (Berl). 2006, 112: 163-174. 10.1007/s00401-006-0077-5.CrossRef

63.

Huse JT, Liu K, Pijak DS, Carlin D, Lee VM-Y, Doms RW: Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer’s disease brain. J Biol Chem. 2002, 277: 16278-16284. 10.1074/jbc.M111141200.CrossRefPubMed

64.

Liu K, Doms RW, Lee VM-Y: Glu11 site cleavage and N-terminally truncated Aβ production upon BACE overexpression. Biochemistry (Mosc). 2002, 41: 3128-3136. 10.1021/bi015800g.CrossRef

65.

Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth H-U: Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004, 563: 191-196. 10.1016/S0014-5793(04)00300-X.CrossRefPubMed

66.

Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth H-U, Rossner S: Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathology. Nat Med. 2008, 14: 1106-1111. 10.1038/nm.1872.CrossRefPubMed

67.

Cynis H, Scheel E, Saido TC, Schilling S, Demuth H-U: Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry (Mosc). 2008, 47: 7405-7413. 10.1021/bi800250p.CrossRef

68.

Jawhar S, Wirths O, Schilling S, Graubner S, Demuth H-U, Bayer TA: Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem. 2011, 286: 4454-4460. 10.1074/jbc.M110.185819.PubMedCentralCrossRefPubMed

69.

Tekirian TL, Yang AY, Glabe C, Geddes JW: Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of Aβ1–40 and -42. J Neurochem. 1999, 73: 1584-1589.CrossRefPubMed

70.

Youssef I, Florent-Béchard S, Malaplate-Armand C, Koziel V, Bihain B, Olivier J-L, Leininger-Muller B, Kriem B, Oster T, Pillot T: N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging. 2008, 29: 1319-1333. 10.1016/j.neurobiolaging.2007.03.005.CrossRefPubMed

71.

He W, Barrow CJ: The Aβ3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length Aβ. Biochemistry (Mosc). 1999, 38: 10871-10877. 10.1021/bi990563r.CrossRef

72.

Christensen DZ, Kraus SL, Flohr A, Cotel M-C, Wirths O, Bayer TA: Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol (Berl). 2008, 116: 647-655. 10.1007/s00401-008-0451-6.CrossRef

73.

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG: Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci. 2001, 21: 372-381.PubMed

74.

Wirths O, Breyhan H, Cynis H, Schilling S, Demuth H-U, Bayer TA: Intraneuronal pyroglutamate-Aβ 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (Berl). 2009, 118: 487-496. 10.1007/s00401-009-0557-5.CrossRef

75.

Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rübsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth H-U, von Hörsten S: Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci Off J Soc Neurosci. 2011, 31: 12790-12801. 10.1523/JNEUROSCI.1794-11.2011.CrossRef

76.

Szendrei GI, Fabian H, Mantsch HH, Lovas S, Nyéki O, Schön I, Otvos L: Aspartate-bond isomerization affects the major conformations of synthetic peptides. Eur J Biochem FEBS. 1994, 226: 917-924. 10.1111/j.1432-1033.1994.t01-1-00917.x.CrossRef

77.

Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zürcher-Neely HA, Heinrikson RL, Ball MJ: Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem. 1993, 268: 3072-3083.PubMed

78.

Fabian H, Szendrei GI, Mantsch HH, Greenberg BD, Otvös L: Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. Eur J Biochem FEBS. 1994, 221: 959-964. 10.1111/j.1432-1033.1994.tb18811.x.CrossRef

79.

Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T: Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer’s disease. J Neurosci Res. 2002, 70: 451-461. 10.1002/jnr.10350.CrossRefPubMed

80.

Fukuda H, Shimizu T, Nakajima M, Mori H, Shirasawa T: Synthesis, aggregation, and neurotoxicity of the Alzheimer’s Aβ1-42 amyloid peptide and its isoaspartyl isomers. Bioorg Med Chem Lett. 1999, 9: 953-956. 10.1016/S0960-894X(99)00121-3.CrossRefPubMed

81.

Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE: Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer’s disease. Biochim Biophys Acta. 1998, 1406: 291-298. 10.1016/S0925-4439(98)00014-3.CrossRefPubMed

82.

Fonseca MI, Head E, Velazquez P, Cotman CW, Tenner AJ: The presence of isoaspartic acid in β-amyloid plaques indicates plaque age. Exp Neurol. 1999, 157: 277-288. 10.1006/exnr.1999.7058.CrossRefPubMed

83.

Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ: Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol. 1996, 149: 1823-1830.PubMedCentralPubMed

84.

Kubo T, Kumagae Y, Miller CA, Kaneko I: Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. J Neuropathol Exp Neurol. 2003, 62: 248-259.PubMed

85.

Tomiyama T, Asano S, Furiya Y, Shirasawa T, Endo N, Mori H: Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J Biol Chem. 1994, 269: 10205-10208.PubMed

86.

Tambo K, Yamaguchi T, Kobayashi K, Terauchi E, Ichi I, Kojo S: Racemization of the aspartic acid residue of amyloid-β peptide by a radical reaction. Biosci Biotechnol Biochem. 2013, 77: 416-418.CrossRefPubMed

87.

Inoue K, Hosaka D, Mochiuki N, Akatsu H, Tsutsumiuchi K, Hashizume Y, Matsukawa N, Yamamoto T, Toyo’oka T: Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer’s brain tissues by covalent chiral derivatized ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem. 2013, 86: 797-804.CrossRefPubMed

88.

Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K: Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patient. Neurodegener Dis. 2012, 10: 138-140. 10.1159/000334537.CrossRefPubMed

89.

Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki H-W, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M: Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm Vienna Austria 1996. 2009, 116: 203-212.

90.

Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Rüther E, Wiltfang J: Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord. 2011, 31: 37-44. 10.1159/000322370.CrossRefPubMed

91.

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T: Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci USA. 2009, 106: 12145-12150. 10.1073/pnas.0904866106.PubMedCentralCrossRefPubMed

92.

Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA: Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer’s disease. Neurobiol Aging. 2011, 32: 1379-1387. 10.1016/j.neurobiolaging.2009.08.011.CrossRefPubMed

93.

Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, Shia MA, Fine RE: Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer’s disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core. Neurosci Lett. 2011, 505: 109-112. 10.1016/j.neulet.2011.09.071.PubMedCentralCrossRefPubMed

Title: Truncated and modified amyloid-beta species
Authors: Markus P Kummer
Michael T Heneka
Publication date: 01-06-2014
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 3/2014
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt258

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Truncated and modified amyloid-beta species

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

Acetylation: a new key to unlock tau’s role in neurodegeneration

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab

Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease

β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice